CEO Discusses Why the Future of Cancer Treatment May Belong to Combination Approaches and How ERNA-101 Was Designed to Turn Immunologically "Cold" Tumors Into Targets for the Immune SystemVideo Showcases Differentiated Off-the-Shelf Cell Therapy Platform, Independent Validation of Complete Tumor Cl…
CEO discusses ERNA-101's potential to transform immunologically "cold" tumors into tumors the immune system can recognize and killVideo highlights compelling preclinical data, differentiated off-the-shelf iMSC platform and progress toward planned first-in-human clinical evaluationIND submission pla…
Ernexa Therapeutics announced that Sandra Gurrola will resign as Senior Vice President of Finance, effective July 3, 2026, and will provide limited transition support.Original SEC Filing: Ernexa Therapeutics Inc. [ ERNA ] - 8-K - Jun. 26, 2026This is an AI-powered summary. It may contain inaccuraci…
